NIH R01 · 2024
Hematopoietic stem cells overcome treatment resistance to PD-1 blockade against brain tumors
PROJECT SUMMARY AND ABSTRACT Harnessing the immune system for the treatment of cancer through PD-1 checkpoint inhibitor has shown considerable promise in a number of solid tumors. Recently, the use of neoadjuvant PD-1 checkpoint blockade demonstrated prolonged overall survival in a randomized study of patients with recurrent glioblastoma. However, outcomes remain poor for these patients, with an observed median survival of 13.2 months and most patients succumbing to disease progression. Our group has found a novel way to overcome treatment resistance to adjuvant αPD-1 monotherapy by employing concomitant transfer of bone marrow-derived hematopoietic stem and progenitor cells (HSC) with PD-1…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.